Ardevora Asset Management LLP increased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 0.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 136,900 shares of the medical instruments supplier’s stock after buying an additional 200 shares during the period. C.R. Bard accounts for about 1.1% of Ardevora Asset Management LLP’s investment portfolio, making the stock its 13th largest position. Ardevora Asset Management LLP owned approximately 0.19% of C.R. Bard worth $34,025,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in C.R. Bard by 5.0% in the fourth quarter. State Street Corp now owns 3,703,576 shares of the medical instruments supplier’s stock valued at $832,035,000 after buying an additional 176,151 shares during the last quarter. Putnam Investments LLC boosted its stake in shares of C.R. Bard by 1.3% in the fourth quarter. Putnam Investments LLC now owns 1,171,703 shares of the medical instruments supplier’s stock valued at $263,235,000 after buying an additional 15,255 shares in the last quarter. APG Asset Management N.V. boosted its stake in shares of C.R. Bard by 22.7% in the first quarter. APG Asset Management N.V. now owns 844,466 shares of the medical instruments supplier’s stock valued at $209,884,000 after buying an additional 156,353 shares in the last quarter. Norges Bank acquired a new stake in shares of C.R. Bard during the fourth quarter valued at $141,560,000. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in shares of C.R. Bard by 82.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 528,921 shares of the medical instruments supplier’s stock valued at $131,458,000 after buying an additional 239,150 shares in the last quarter. Hedge funds and other institutional investors own 88.32% of the company’s stock.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Shares of C.R. Bard, Inc. (BCR) opened at 313.56 on Friday. The firm has a 50-day moving average price of $309.48 and a 200 day moving average price of $257.26. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $315.29. The stock has a market cap of $22.71 billion, a price-to-earnings ratio of 39.91 and a beta of 0.64.

C.R. Bard (NYSE:BCR) last posted its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The company had revenue of $938.80 million for the quarter, compared to the consensus estimate of $916.15 million. During the same period in the previous year, the business earned $2.34 earnings per share. C.R. Bard’s quarterly revenue was up 7.5% compared to the same quarter last year. Analysts expect that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be given a $0.26 dividend. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.21%.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/06/17/ardevora-asset-management-llp-increases-stake-in-c-r-bard-inc-bcr-updated-updated.html.

BCR has been the subject of a number of recent analyst reports. BMO Capital Markets lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 target price for the company. in a research note on Tuesday, April 25th. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price for the company in a research note on Tuesday. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Cowen and Company upped their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. Finally, Jefferies Group LLC upped their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research note on Monday, April 24th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $265.62.

In other news, VP Frank Lupisella, Jr. sold 3,622 shares of the company’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the sale, the vice president now directly owns 10,139 shares in the company, valued at $3,082,256. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.80% of the stock is owned by corporate insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.